Demand for natural food and wellness products has creating incredible opportunity for the functional mushroom market. So much so that consumers are craving mushroom coffees and teas for an “added super food go-to morning beverage,” notes Yahoo Life.
After all, according to Penny White, CEO of Better Plant Sciences, “Functional mushrooms are increasing in popularity for their ability to increase mental clarity, as well as for their range of health benefits, including immune support and energy-boosting qualities. We have formulated our coffees to be both healthy and delicious, and our instant blend is convenient, easy, and perfect for those on the go or those who are only looking to enjoy one cup at a time.”
Reportedly, mushrooms such as Reishi can help with sleep, anxiety, and depression, according to Teelixir. Lion’s mane can help with memory, according to Healthline. Chaga can help with inflammation for example, according to Best Products. Turkey tail can help support the immune system, and assist with some cancer prevention, says Healthline
“Mushrooms have long been used in Chinese medicine and newer research shows they are the highest dietary source of the antioxidants ergothioneine and glutathione, which help protect the body against the type of damage that can eventually contribute to age-related diseases like cancer, heart disease, Parkinson’s and Alzheimer’s,” says Beth Warren, RDN, author of Secrets of a Kosher Girl. “Mushroom coffees and teas can give anyone a boost, but they may be especially beneficial for those who are dealing with chronic diseases and inflammation.”
Functional Mushrooms are Helping to Fuel Better Plant Sciences (CSE: PLNT) (OTCQB: VEGGF)
Better Plant Sciences just announced that its majority owned subsidiary NeonMind Biosciences just completed production of two out of four of its superfood mushroom coffee blends.
The first NeonMind Superfood instant coffees will be ready to ship to its warehouse in early November. The initial two formulas are an Ayurveda-inspired blend of reishi, lion’s mane, ashwagandha and turmeric with premium instant coffee. The medicinal mushrooms are antioxidant and nutrient-rich, with adaptogenic, immune-boosting properties. The Company plans to launch its eCommerce website in November and will rely heavily on influencer marketing to educate a broader consumer base on the taste and health benefits of mushroom coffees.
Having just completed manufacturing of the two instant coffee blends, they will now undergo third-party testing as required by Health Canada regulations, and are expected to be ready to ship to our warehouse in early November.
They will then begin manufacturing two brewed coffee formulations, with production to be followed by the same required third-party testing. The brewed coffees are expected to be ready to ship to our warehouse in mid-November. All four products have been registered with Vancouver Coastal Health. The Company’s plan is to commercially launch the mushroom coffees via a new eCommerce website in late November 2020.
For more information, visit the company’s website at https://betterplantsciences.com.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media and Better Plant Sciences Inc., Winning Media has been paid two thousand dollars for advertising and marketing services for Better Plant Sciences Inc. We own ZERO shares of Better Plant Sciences Inc. Please click here for full disclaimer.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66489
News Provided by Newsfile via QuoteMedia
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.
DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.